Wednesday, October 22, 2025
HomeUncategorizedMBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete...

MBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete with Ascendis, AstraZeneca

MBX Bio­sciences said Mon­day that its ex­per­i­men­tal drug can­vu­paratide cleared the bar in a Phase 2 tri­al in a rare en­docrine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments